Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Overprescribing of Antidepressant Medications May Be Common in Elderly Patients

In a Pharmacology Research & Perspectives study of individuals living in Olmsted County, Minnesota from 2005–2012, potential overprescribing of antidepressant medications occurred in nearly one-quarter of elderly residents.

Thursday, January 24, 2019 12:01 am EST
"Our results, in agreement with others, suggest that the potential overprescribing of antidepressants may occur more often in elderly people who have a higher degree of clinical complexity or severity"

In a Pharmacology Research & Perspectives study of individuals living in Olmsted County, Minnesota from 2005–2012, potential overprescribing of antidepressant medications occurred in nearly one-quarter of elderly residents.

Potential antidepressant overprescribing was most likely in individuals residing in nursing homes; patients having a higher number of comorbid medical conditions; individuals who were outpatients; those taking more concomitant medications; those having greater use of acute care services; and those receiving prescriptions via telephone, e-mail, or patient portal.

“Our results, in agreement with others, suggest that the potential overprescribing of antidepressants may occur more often in elderly people who have a higher degree of clinical complexity or severity,” said lead author Dr. William Bobo, of the Mayo Clinic, in Jacksonville, Florida. “This is important to consider because these individuals may be at especially high risk for clinically significant depression, and clinicians may be left with relatively little time to discuss the individual concerns that may prompt the issuing of an antidepressant prescription. This is something that we would like to look into in future studies. 

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/full/10.1002/prp2.461  

About Journal 

PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS.

About Wiley

Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at www.wiley.com.

Multimedia Files:

Preview image

Contact:

Josh Glickman +1 201-748-6572 (US)
Penny Smith +44 (0) 1243 770448 (UK)
newsroom@wiley.com

Business Wire NewsHQsm